clinical trial · NCT04557059
A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer
Janssen Pharmaceutica N.V., Belgium·phase3·active not recruiting·n = 693
Prostatic NeoplasmsRadiotherapyLHRHaApalutamide
brief summary
The main purpose of this study is to determine if the addition of apalutamide to radiotherapy (RT) plus luteinizing hormone-releasing hormone agonist (LHRHa) delays metastatic progression as assessed by prostate specific membrane antigen-positron emission tomography (PSMA-PET) or death compared with RT plus LHRHa alone.
started
Nov 12, 2020
primary completion
Aug 27, 2029
completion
Aug 27, 2029
last updated
Apr 13, 2026
official title
A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer, Assessed by PSMA-PET With an Observational Cohort
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol